CNP
50
-2
EQR
60
6
QCOM
55
-2
LB
63
-4
DG
12
2
PCG
99
2
OXY
55
6
NKE
33
2
SYF
93
-2
GILD
56
-4
SWK
56
-6
NSC
64
2
SCHW
65
-2
GPC
40
2
REGN
42
-2
MU
32
-6
MRO
46
3
SJM
16
-3
CVX
38
6
ACN
70
5
CNP
50
-2
EQR
60
6
QCOM
55
-2
LB
63
-4
DG
12
2
PCG
99
2
OXY
55
6
NKE
33
2
SYF
93
-2
GILD
56
-4
SWK
56
-6
NSC
64
2
SCHW
65
-2
GPC
40
2
REGN
42
-2
MU
32
-6
MRO
46
3
SJM
16
-3
CVX
38
6
ACN
70
5
Financhill
Back

Aligos Therapeutics 10K Form

Buy
69

ALGS
Aligos Therapeutics

Last Price:
19.46
Seasonality Move:
0%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ALGS News And Ratings

See the #1 stock for the next 7 days that we like better than ALGS

ALGS Financial Statistics

Sales & Book Value

Annual Sales: $15.53M
Cash Flow: $-20.13M
Price / Cash Flow: 0
Annual Sales: $15.07
Price / Book: 1.39

Profitability

EPS (TTM): -17.10530
Net Income (TTM): $-76.95M
Gross Margin: --
Return on Equity: -118.75%
Return on Assets: -68.4%

Aligos Therapeutics Earnings Forecast

Key Aligos Therapeutics Financial Ratios

  • The Research & Development expenses have been 470.35% of Revenue.
  • The Net Earning history of ALGS is -564.61% of Total Revenues.
  • Per Share Earnings over the last 5 years have been positive in 3 years.

Aligos Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: ALGS
Website: aligos.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 3.81
Quick Ratio: 3.58

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ALGS Technical Analysis vs Fundamental Analysis

Buy
69
Aligos Therapeutics (ALGS) is a Buy

Is Aligos Therapeutics a Buy or a Sell?